{
  "ticker": "ALNY",
  "company_name": "Alnylam Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03774784",
      "title": "A Study of the Natural History of Leukocyte Chemotactic Factor 2 Amyloidosis (ALECT2) Disease",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis",
      "start_date": "2019-01-29",
      "completion_date": "2020-05-18",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT03303313",
      "title": "A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Atypical Hemolytic Uremic Syndrome",
      "start_date": "2017-09-19",
      "completion_date": "2018-09-12",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT00496821",
      "title": "Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Respiratory Syncytial Virus Infections",
      "start_date": "2007-07",
      "completion_date": "2007-11",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT05940922",
      "title": "RWE-based Treatment Patterns and Outcomes in CIDP",
      "status": "UNKNOWN",
      "phase": "",
      "condition": "Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis",
      "start_date": "2023-08-17",
      "completion_date": "2023-10-30",
      "enrollment": 0,
      "sponsor": "RwHealth"
    },
    {
      "nct_id": "NCT02053454",
      "title": "A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Transthyretin (TTR)-Mediated Amyloidosis",
      "start_date": "2014-01",
      "completion_date": "2014-06",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT05256810",
      "title": "A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Gout",
      "start_date": "2022-02-25",
      "completion_date": "2023-01-25",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT02252653",
      "title": "DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Familial Amyloidotic Cardiomyopathy (FAC)",
      "start_date": "2014-06",
      "completion_date": "2016-03",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT01960348",
      "title": "APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related",
      "start_date": "2013-11",
      "completion_date": "2017-08",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT01148953",
      "title": "Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Transthyretin Mediated Amyloidosis (ATTR)",
      "start_date": "2010-06",
      "completion_date": "2012-02",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    },
    {
      "nct_id": "NCT01981837",
      "title": "Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "TTR-mediated Amyloidosis",
      "start_date": "2013-12",
      "completion_date": "2015-01",
      "enrollment": 0,
      "sponsor": "Alnylam Pharmaceuticals"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "": 13,
      "PHASE2": 14,
      "PHASE1": 11,
      "PHASE1, PHASE2": 4,
      "PHASE3": 7,
      "EARLY_PHASE1": 1
    },
    "by_status": {
      "TERMINATED": 8,
      "WITHDRAWN": 1,
      "COMPLETED": 24,
      "UNKNOWN": 1,
      "RECRUITING": 7,
      "ACTIVE_NOT_RECRUITING": 4,
      "APPROVED_FOR_MARKETING": 2,
      "ENROLLING_BY_INVITATION": 1,
      "NOT_YET_RECRUITING": 1,
      "NO_LONGER_AVAILABLE": 1
    },
    "active_trials": 12,
    "completed_trials": 24,
    "conditions": [
      "Acute Hepatic Porphyria",
      "Acute Hepatic Porphyria, Hepatic Porphyrias, Acute Intermittent Porphyria (AIP), Hereditary Coproporphyria (HCP), Variegate Porphyria (VP), ALA Dehydratase Deficient Porphyria (ADP), Porphyria Acute",
      "Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma",
      "Amyloidosis, Familial, Transthyretin Amyloidosis",
      "Amyloidosis, Leukocyte Chemotactic Factor 2 Amyloidosis",
      "Atypical Hemolytic Uremic Syndrome",
      "Cerebral Amyloid Angiopathy",
      "Chronic Hepatitis B",
      "Chronic Inflammatory Demyelinating Polyneuropathy, Guillain-Barre Syndrome, Hereditary Amyloidosis",
      "Early-Onset Alzheimer Disease",
      "Familial Amyloidotic Cardiomyopathy (FAC)",
      "Gout",
      "Haemodialysis, Chronic Kidney Disease Requiring Chronic Dialysis, Cardiovascular Disease, Cardiovascular Risk Factor, Hyperoxalemia",
      "Healthy",
      "Healthy Volunteers",
      "Hepatitis B, Chronic Hepatitis B, Hepatitis B, Chronic, Hepatitis B Infection, HBV",
      "Hereditary Transthyretin-mediated (ATTRv) Amyloidosis, Polyneuropathy",
      "Hypertension",
      "IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA",
      "Nonalcoholic Steatohepatitis, NASH",
      "Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)",
      "PH1, Primary Hyperoxaluria, RNAi Therapeutic, siRNA, AGT",
      "Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis",
      "Primary Hyperoxaluria",
      "Primary Hyperoxaluria Type 1",
      "Primary Hyperoxaluria Type 1 (PH1)",
      "Primary Hyperoxaluria Type 1, Primary Hyperoxaluria",
      "Primary Hyperoxaluria, Primary Hyperoxaluria Type 1 (PH1)",
      "Recurrent Calcium Oxalate Kidney Stone Disease, Elevated Urinary Oxalate Levels",
      "Respiratory Syncytial Virus Infections",
      "TTR-mediated Amyloidosis",
      "TTR-mediated Amyloidosis, Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Familial Amyloid Polyneuropathies, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related",
      "Transthyretin (TTR)-Mediated Amyloidosis",
      "Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP), ATTR Amyloidosis, Familial Amyloid Neuropathies",
      "Transthyretin Amyloidosis (ATTR) With Cardiomyopathy",
      "Transthyretin Amyloidosis With Cardiomyopathy",
      "Transthyretin Amyloidosis, Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Polyneuropathies, Cardiomyopathies",
      "Transthyretin Mediated Amyloidosis (ATTR)",
      "Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis",
      "Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)",
      "Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy",
      "Type 2 Diabetes Mellitus (T2DM)"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:16:13.422807",
    "search_query": "Alnylam Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Alnylam+Pharmaceuticals,+Inc."
  }
}